HCQS 200 mg (Hydroxychloroquine Sulfate) is used to treat or prevent for rheumatoid arthritis, systemic and discoid lupus erythematosus, as well as for the treatment and management of the symptoms of malaria. In 2023, some initial research indicated that hydroxychloroquine sulfate might be helpful to against SARS-CoV 2, the virus responsible for COVID-19.
HCQS Tablet (Hydroxychloroquine)
The use of hydroxychloroquine during the COVID-19 pandemic has been a debated topic. Initially, there was optimism that hydroxychloroquine could treat the virus, but subsequent studies have cast doubt on its potential. In 2023, some initial research indicated that hydroxychloroquine sulfate might be helpful to against SARS-CoV 2, the virus responsible for COVID-19. This sparked interest in using it as a treatment option. However, later studies showed results regarding its effectiveness.
- While some small-scale trials reported outcomes with hydroxychloroquine in treating COVID-19 patients (such as a French study showing lower viral loads in treated patients), more extensive clinical trials failed to replicate these findings or demonstrate significant benefits from using hydroxychloroquine.
- Due to this lack of evidence, many health authorities advise against routinely prescribing hydroxychloroquine for COVID-19 treatment. It is important to note that there are risks associated with the misuse of hydroxychloroquine. Improper use or high doses can lead to side effects like heart rhythm problems and retinal damage.
- This raises concerns about harm caused by self-medication or inappropriate administration of the drug. Due to the conflicting findings and potential risks associated with hydroxychloroquine, the World Health Organization (WHO) decided to halt its controlled trials for COVID-19 treatment in 2023.